Search Results

You are looking at 1 - 2 of 2 items for

  • Author or Editor: Lisa M. Carioto x
  • Refine by Access: All Content x
Clear All Modify Search

Abstract

OBJECTIVE To assess the prevalences of anemia and various RBC anomalies in dogs with lymphoma versus inflammatory bowel disease (IBD) and to evaluate potential relationships between these variables and the severity of lymphoma.

DESIGN Retrospective cross-sectional study.

ANIMALS 82 client-owned dogs.

PROCEDURES Medical records and blood smears were reviewed for dogs in which IBD or lymphoma had been diagnosed between January 1, 2006, and December 31, 2014, and for healthy dogs evaluated during that time frame. Hematologic data were analyzed, and results were compared among groups of healthy dogs, dogs with IBD, and dogs with lymphoma. Results were also compared within the lymphoma group between dogs further grouped on the basis of lymphoma clinical stage, substage, and cell size.

RESULTS Prevalence of anemia was significantly higher in dogs with lymphoma (17/32 [53%]) than in dogs with IBD (5/23 [22%]). The total number of different RBC anomalies was significantly higher in dogs with lymphoma than in dogs that were healthy or had IBD. A cutoff of 3 different RBC anomalies/dog enabled differentiation between lymphoma and IBD, with a sensitivity and specificity of 71% and 70%, respectively (area under the fitted curve, 0.7239 ± 0.0727). The presence of eccentrocytes was the only individual RBC anomaly significantly more common in dogs with lymphoma (8/28 [29%]) versus dogs with IBD (1/23 [4%]).

CONCLUSIONS AND CLINICAL RELEVANCE Results suggested that detection of anemia combined with ≥ 3 RBC morphological anomalies, particularly eccentrocytes, on blood smears should increase the clinical suspicion of lymphoma, compared with IBD, in dogs.

Full access
in Journal of the American Veterinary Medical Association

Abstract

Objectives—To determine whether telomerase activity was present in lymph nodes, buffy coat, and serum samples from dogs with malignant lymphoma (ML) and in liver, lymph node, buffy coat, and serum samples from clinically normal dogs

Sample Population—Tissue specimens and blood samples were obtained from 11 clinically normal adult dogs (age range, 1 to 4 years) and 14 client-owned dogs with ML.

Procedure—The telomere repeat amplification protocol assay was used to quantify telomerase activity in the tissues from clinically normal dogs and dogs with ML.

Results—Of 11 clinically normal dogs, 8 had lymph node samples, 5 had liver samples, and 1 had buffy coat samples with detectable telomerase activity. None of the serum samples from the clinically normal dogs had detectable telomerase activity. Of 14 dogs with ML, 9 had lymph node samples, 3 had buffy coat samples, and 1 had serum samples with measurable telomerase activity.

Conclusions and Clinical Relevance—Telomerase activity was not specific to tumor cells and overlapped with that found in cells from clinically normal dogs. Telomerase activity in neoplastic lymph nodes was not substantially different from that found in lymph nodes from clinically normal dogs. The determination of telomerase activity cannot be used as a sole diagnostic test for cancer. Therapeutic modalities directed toward the telomerase enzyme may not be feasible in dogs, because somatic tissues from clinically normal dogs possess variable amounts of telomerase activity. (Am J Vet Res 2001;62:1442–1446)

Full access
in American Journal of Veterinary Research